Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL

Christopher Kim, Julia T. Molony, Victoria M. Chia, Vamsi K. Kota, Aaron J. Katz, Shuling Li

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100% Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5%) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4% received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8% received both chemotherapy and TKIs, 9.8% received steroids only and 2.6% received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8% received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7%) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4%). Overall, 67.5% of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.

Original languageEnglish (US)
Pages (from-to)1462-1468
Number of pages7
JournalLeukemia and Lymphoma
Volume60
Issue number6
DOIs
StatePublished - May 12 2019

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mortality
Protein-Tyrosine Kinases
Drug Therapy
Therapeutics
Comorbidity
Medicare
Steroids

Keywords

  • Acute lymphoblastic leukemia
  • Medicare
  • claims
  • survival
  • treatment patterns

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. / Kim, Christopher; Molony, Julia T.; Chia, Victoria M.; Kota, Vamsi K.; Katz, Aaron J.; Li, Shuling.

In: Leukemia and Lymphoma, Vol. 60, No. 6, 12.05.2019, p. 1462-1468.

Research output: Contribution to journalArticle

Kim, Christopher ; Molony, Julia T. ; Chia, Victoria M. ; Kota, Vamsi K. ; Katz, Aaron J. ; Li, Shuling. / Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 6. pp. 1462-1468.
@article{9225b78d780640018478f98abe50077f,
title = "Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL",
abstract = "To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100{\%} Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5{\%}) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4{\%} received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8{\%} received both chemotherapy and TKIs, 9.8{\%} received steroids only and 2.6{\%} received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8{\%} received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7{\%}) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4{\%}). Overall, 67.5{\%} of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.",
keywords = "Acute lymphoblastic leukemia, Medicare, claims, survival, treatment patterns",
author = "Christopher Kim and Molony, {Julia T.} and Chia, {Victoria M.} and Kota, {Vamsi K.} and Katz, {Aaron J.} and Shuling Li",
year = "2019",
month = "5",
day = "12",
doi = "10.1080/10428194.2018.1538505",
language = "English (US)",
volume = "60",
pages = "1462--1468",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with ALL

AU - Kim, Christopher

AU - Molony, Julia T.

AU - Chia, Victoria M.

AU - Kota, Vamsi K.

AU - Katz, Aaron J.

AU - Li, Shuling

PY - 2019/5/12

Y1 - 2019/5/12

N2 - To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100% Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5%) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4% received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8% received both chemotherapy and TKIs, 9.8% received steroids only and 2.6% received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8% received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7%) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4%). Overall, 67.5% of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.

AB - To describe patient characteristics and treatment patterns among elderly patients (≥66 years) newly diagnosed with acute lymphoblastic leukemia (ALL), we analyzed 100% Medicare ALL data from 2007 to 2015. Only 764 out of 1428 (53.5%) elderly patients received treatment within 90 d of diagnosis with ≥30-d follow-up; 32.4% received chemotherapy without tyrosine kinase inhibitors (TKIs), 8.8% received both chemotherapy and TKIs, 9.8% received steroids only and 2.6% received TKIs only. Among 717 patients receiving chemotherapy any time during follow-up, 65.8% received only one course of treatment. Patients treated with chemotherapy or TKIs compared to untreated patients were younger (<75 years: 51.5 vs. 21.7%) and had a lower comorbidity burden (Charlson Comorbidity index ≤ 2: 90.9 vs. 71.4%). Overall, 67.5% of patients died within 3 years of diagnosis. Our findings demonstrate that many elderly ALL patients are not treated in the real-world setting and highlight the need for tolerable therapies for these patients.

KW - Acute lymphoblastic leukemia

KW - Medicare

KW - claims

KW - survival

KW - treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=85058640431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058640431&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1538505

DO - 10.1080/10428194.2018.1538505

M3 - Article

C2 - 30541363

AN - SCOPUS:85058640431

VL - 60

SP - 1462

EP - 1468

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -